Infants with B-ALL harboring germline MLL genes show superior responses to chemotherapy compared to those with rearranged MLL genes, achieving a 5-year event-free survival rate of 95.5% with manageable treatment toxicity (17). The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.